CD166/Activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion

Neuro-Oncology

Volumn 14, Issue 10, 2012, Pages 1254-1264

  Kijima, Noriyuki ^a   Hosen, Naoki ^a   Kagawa, Naoki ^a   Hashimoto, Naoya ^a   Nakano, Akiko ^b   Fujimoto, Yasunori ^a   Kinoshita, Manabu ^a   Sugiyama, Haruo ^a   Yoshimine, Toshiki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NOTRE DAME HOSPITAL   (Canada)

Author keywords

activated leukocyte cell adhesion molecule; cancer stem cell; CD166; glioblastoma; invasion

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ISOCITRATE DEHYDROGENASE 1; SMALL INTERFERING RNA;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER PROGNOSIS; CANCER STEM CELL; CELL PROLIFERATION; CONTROLLED STUDY; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; TUMOR GROWTH;

ACTIVATED-LEUKOCYTE CELL ADHESION MOLECULE; ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; FLOW CYTOMETRY; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; ISOCITRATE DEHYDROGENASE; MALE; MICE; MICE, SCID; MUTATION; NEOPLASM GRADING; NEOPLASM INVASIVENESS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; STEM CELLS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866946180     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor202     Document Type: Article

References (45)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352: 987-996.
2. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432: 396-401.
3. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64: 7011-7021.
4. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444: 756-760.
5. Son MJ, Woolard K, Nam DH, Lee J, Fine HA. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 2009;4: 440-452.
6. Ogden AT, Waziri AE, Lochhead RA, et al. Identification of A2B5+CD133-tumor-initiating cells in adult human gliomas. Neurosurgery. 2008;62: 505-514. discussion 14-5.
7. Bao S, Wu Q, Li Z, et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 2008;68: 6043-6048.
8. Lathia JD, Gallagher J, Heddleston JM, et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell. 2010;6: 421-432.
9. Teodorczyk M, Martin-Villalba A. Sensing invasion: cell surface receptors driving spreading of glioblastoma. J Cell Physiol. 2010;222: 1-10.
10. Perego C, Vanoni C, Massari S, et al. Invasive behaviour of glioblastoma cell lines is associated with altered organisation of the cadherin-catenin adhesion system. J Cell Sci. 2002;115: 3331-3340.
11. Owens GC, Orr EA, DeMasters BK, Muschel RJ, Berens ME, Kruse CA. Overexpression of a transmembrane isoform of neural cell adhesion molecule alters the invasiveness of rat CNS-1 glioma. Cancer Res. 1998;58: 2020-2028.
12. Fukushima Y, Ohnishi T, Arita N, Hayakawa T, Sekiguchi K. Integrin alpha3beta1-mediated interaction with laminin-5 stimulates adhesion, migration and invasion of malignant glioma cells. Int J Cancer. 1998;76: 63-72.
13. Tanaka H, Matsui T, Agata A, et al. Molecular cloning and expression of a novel adhesion molecule, SC1. Neuron. 1991;7: 535-545.
14. Johnston IG, Paladino T, Gurd JW, Brown IR. Molecular cloning of SC1: a putative brain extracellular matrix glycoprotein showing partial similarity to osteonectin/BM40/SPARC. Neuron. 1990;4: 165-176.
15. Burns FR, von Kannen S, Guy L, Raper JA, Kamholz J, Chang S. DM-GRASP, a novel immunoglobulin superfamily axonal surface protein that supports neurite extension. Neuron. 1991;7: 209-220.
16. Ohneda O, Ohneda K, Arai F, et al. ALCAM (CD166): its role in hem-atopoietic and endothelial development. Blood. 2001;98: 2134-2142.
17. Cayrol R, Wosik K, Berard JL, et al. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol. 2008;9: 137-145.
18. Nakamura Y, Arai F, Iwasaki H, et al. Isolation and characterization of endosteal niche cell populations that regulate hematopoietic stem cells. Blood. 2010;116: 1422-1432.
19. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284: 143-147.
20. Bruder SP, Ricalton NS, Boynton RE, et al. Mesenchymal stem cell surface antigen SB-10 corresponds to activated leukocyte cell adhesion molecule and is involved in osteogenic differentiation. J Bone Miner Res. 1998;13: 655-663.
21. Uchida N, Yang Z, Combs J, et al. The characterization, molecular cloning, and expression of a novel hematopoietic cell antigen from CD34+ human bone marrow cells. Blood. 1997;89: 2706-2716.
22. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA. 2007;104: 10158-10163.
23. Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI. Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-kappaB signalling. Nat Commun. 2011;2: 162.
24. Ofori-Acquah SF, King JA. Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res. 2008;151: 122-128.
25. Lunter PC, van Kilsdonk JW, van Beek H, et al. Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res. 2005;65: 8801-8808.
26. van Kempen LC, Meier F, Egeblad M, et al. Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis. J Invest Dermatol. 2004;122: 1293-1301.
27. Ikeda K, Quertermous T. Molecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell function. J Biol Chem. 2004;279: 55315-55323.
28. van Kilsdonk JW, Wilting RH, Bergers M, et al. Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule. Cancer Res. 2008;68: 3671-3679.
29. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quan-titating the invasive potential of tumor cells. Cancer Res. 1987;47: 3239-3245.
30. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360: 765-773.
31. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321: 1807-1812.
32. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009;11: 341-347.
33. Nobusawa SWT, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15: 6002-6007.
34. Mellai MPA, Caldera V, Monzeglio O, Cassoni P, Valente G, Schiffer D. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. J Neurooncol. 2011;105(2): 345-357.
35. Preusser M, Wohrer A, Stary S, et al. Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of the IDH1-R132H Mutation in Diffuse Glioma Biopsy Specimens. J Neuropathol Exp Neurol. 2011;70: 715-723.
36. Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007;67: 4010-4015.
37. Wang J, Sakariassen PO, Tsinkalovsky O, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer. 2008;122: 761-768.
38. Burkhardt M, Mayordomo E, Winzer KJ, et al. Cytoplasmic overexpres-sion of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol. 2006;59: 403-409.
39. Weichert W, Knosel T, Bellach J, Dietel M, Kristiansen G. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol. 2004;57: 1160-1164.
40. Kahlert C, Weber H, Mogler C, et al. Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer. 2009;101: 457-464.
41. van Kempen LC, van den Oord JJ, van Muijen GN, Weidle UH, Bloemers HP, Swart GW. Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol. 2000;156: 769-774.
42. Kristiansen G, Pilarsky C, Wissmann C, et al. ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate. 2003;54: 34-43.
43. King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG. Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res. 2004;6: R478-R487.
44. Ihnen M, Muller V, Wirtz RM, et al. Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat. 2008;112: 419-427.
45. Mezzanzanica D, Fabbi M, Bagnoli M, et al. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res. 2008;14: 1726-1733.